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RESEARCH ARTICLE
N-Acetylcysteine Targets 5 Lipoxygenase-
Derived, Toxic Lipids and Can Synergize
With Prostaglandin E2 to Inhibit
Ferroptosis and Improve Outcomes
Following Hemorrhagic Stroke in Mice
Saravanan S. Karuppagounder, PhD,1,2 Lauren Alin, BS,1,2 Yingxin Chen, MD,1,2
David Brand, BS,1,2 Megan W. Bourassa, PhD,1,2 Kristen Dietrich, BS,3
Cassandra M. Wilkinson, BS,4 Colby A. Nadeau, MS,4 Amit Kumar, PhD,1,2
Steve Perry, PhD,5 John T. Pinto, PhD,6 Victor Darley-Usmar, PhD,7
Stephanie Sanchez, PhD,8 Ginger L. Milne, PhD,8 Domenico Pratico, MD,9
Theodore R. Holman, PhD,5 S. Thomas Carmichael, MD, PhD,10 Giovanni Coppola, MD,11
Frederick Colbourne, PhD,3,4 and Rajiv R. Ratan, MD, PhD1,2
Objectives: N-acetylcysteine (NAC) is a clinically approved thiol-containing redox modulatory compound currently in
trials for many neurological and psychiatric disorders. Although generically labeled as an “antioxidant,” poor under-
standing of its site(s) of action is a barrier to its use in neurological practice. Here, we examined the efficacy and mech-
anism of action of NAC in rodent models of hemorrhagic stroke.
Methods: Hemin was used to model ferroptosis and hemorrhagic stroke in cultured neurons. Striatal infusion of colla-
genase was used to model intracerebral hemorrhage (ICH) in mice and rats. Chemical biology, targeted lipidomics, ara-
chidonate 5-lipoxygenase (ALOX5) knockout mice, and viral-gene transfer were used to gain insight into the
pharmacological targets and mechanism of action of NAC.
Results: NAC prevented hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent
ALOX5 activity. NAC efficacy required increases in glutathione and is correlated with suppression of reactive lipids by
glutathione-dependent enzymes such as glutathione S-transferase. Accordingly, its protective effects were mimicked by
chemical or molecular lipid peroxidation inhibitors. NAC delivered postinjury reduced neuronal death and improved func-
tional recovery at least 7 days following ICH in mice and can synergize with clinically approved prostaglandin E2 (PGE2).
Interpretation: NAC is a promising, protective therapy for ICH, which acted to inhibit toxic arachidonic acid products
of nuclear ALOX5 that synergized with exogenously delivered protective PGE2 in vitro and in vivo. The findings provide
novel insight into a target for NAC, beyond the generic characterization as an antioxidant, resulting in neuroprotection
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and offer a feasible combinatorial strategy to optimize efficacy and safety in dosing of NAC for treatment of neurologi-
cal disorders involving ferroptosis such as ICH.
ANN NEUROL 2018;84:854–872
Hemorrhagic stroke, defined as bleeding within thebrain parenchyma, accounts for 13% to 15% of all
stroke cases. Nearly half of patients afflicted die, and for
those that who survive, long-term disability is common.1,2
Identification of novel targets to treat this disease is an
important unmet public need.
N-acetylcysteine (NAC) is an US Food and Drug
Administration–approved cysteine prodrug, established for
its role in treating acetaminophen-induced liver failure3 and
other non-CNS (central nervous system) indications.4,5
Considerable preclinical data have accumulated to support
the use of NAC in the CNS in acute and chronic neurolog-
ical conditions as well as neuropsychiatric disorders.6–9
Recent studies show that NAC inhibits ferroptosis
in vitro,10 and because ferroptosis appears to be a mecha-
nism of cell loss in hemorrhagic stroke in vivo in rodent
models,10,11 we considered its use for this stroke sub-type.
Among the challenges in moving NAC forward as a
therapeutic for CNS disorders are its many putative targets
of action. Indeed, NAC has been thought to have broad
salutary effects in diverse animal models by its ability to
affect multiple targets. For example, NAC increases levels
of cellular cysteine. Cysteine is the rate-limiting precursor
for glutathione synthesis. Glutathione acts as a co-factor
with a number of distinct antioxidant and detoxifying
enzymes.12
NAC can also enhance CNS function through
increases in glutamatergic neurotransmission. It accom-
plishes this by driving activity of the X −c transporter, a cys-
tine/glutamate antiporter, which pumps glutamate out of
cells in exchange for NAC-derived cyste(i)ne.13 NAC acts
on immune cells to inhibit proinflammatory cytokines
tumor necrosis factor alpha and interleukin-1β in preclini-
cal ischemic models14; or to improve mitochondrial dys-
function in a model of Huntington’s disease15 or
traumatic brain injury in rats.16 Also, high-dose NAC has
been shown to inhibit neurotropic Sindbis virus–induced
apoptosis, in part by suppressing prodeath, nuclear factor
kappa B signaling.17 Finally, NAC was recently shown to
have a thrombolytic effect on occlusive arterial clot.18
Because NAC has many putative targets, it has been
assumed that its salutary effects cannot be correlated with
any single target. Accordingly, deciding on an optimal
dose of NAC to use in the CNS has been challenging.
Because CNS penetration of NAC is also poor,8 in the
absence of a bona-fide target, it is difficult to know
whether current systemic administration is adequate to
achieve therapeutic concentrations in the CNS. The need
to identify a therapeutic target is further underscored by
other factors, which constrain the clinical applications of
NAC. Although NAC is believed to be generally safe, it
has been reported to dose dependently cause nausea and
vomiting, induce bronchospasm, slow blood clotting, and
induce neurotoxicity, which could be problematic for
patients with stroke, especially of the hemorrhagic
subtype.
Therefore, the goal of this study was to understand
whether NAC is effective in models of intracerebral
hemorrhage (ICH); if so, to identify the target of its
action as a first step toward defining the optimal dose
in vivo for functional recovery. Here, we show that
NAC acts therapeutically as a precursor for glutathione
which in turn together with glutathione dependent
enzymes (eg, glutathione S-transferases [GSTs]) targets
lipid-derived reactive electrophilic species derived from
increased arachidonate 5-lipoxygenase (ALOX5). We
also show that simultaneous, exogenous infusion of a
clinically approved, protective lipid species, prostaglan-
din E2 (PGE2), can reduce the concentration of NAC
required to stimulate protection and functional recovery
in vitro or in vivo in mice.
Materials and Methods
Animals
C57BL/6 and pregnant CD1 mice of 10 to 12 weeks were pur-
chased from Charles River Laboratories (Wilmington, MA).
Homozygous ALOX5 knockout (ALOX-5–/–) mice were
obtained from The Jackson Laboratory (Bar Harbor, ME). Ani-
mals were housed in a pathogen-free facility on a 12-hour light/
dark cycle and, unless otherwise stated, provided ad libitum
access to food and water. All mice and procedures were approved
by the Institutional Animal Care and Use Committee of the
Weill Cornell Medical College (New York, NY) and were in
accord with the guidelines established by National Institutes of
Health. Rat experiments were approved and conducted at the
University of Alberta (Edmonton, Alberta, Canada) according to
published methods.19,20 Briefly, 219 adult male Sprague–Dawley
rats (350–400g; Charles River Laboratories, Montreal, Quebec,
Canada) were used in several studies to examine the effects of
NAC (40 or 75mg/kg given intraperitoneally [IP] 2 hours after
collagenase infusion and thereafter as in the mice efficacy studies,
versus saline control). We assessed body temperature, edema,
eicosanoids, cerebral bleeding, behavior, and lesion volume (out
to a 28-day survival). Animals were randomly assigned to groups
and data were analyzed blinded.
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Primary Cortical Neuronal Cultures
Primary cortical neurons were prepared as previously described.21
Briefly, cortices were dissected from embryonic (E15.5) CD1
mice, homogenized, papain digested, and cells were plated in
minimum essential medium containing 10% fetal bovine serum,
5% horse serum, and 1% penicillin/streptomycin in 96-well
plates, six-well plates, or 10-cm dishes. Neurons were maintained
at 37C with 5% CO2. All experiments were started at 24 hours
after plating.
In Vitro ICH Model
Blood breakdown product, hemin, was used to induce cell death in
primary cortical neurons. For the protective studies, cells were treated
with hemin (100 μM) in the presence of NAC (0.01–1.00mM), Tro-
lox (0.1–100.0 μM), α-lipoic acid (0.01–2.00mM), U 73122
(0.1–100.0 μM), β carotene (0.1–100.0 μM), MS-PPOH (0.1–
100.0 μM), aspirin (0.1–100.0 μM), celecoxib (0.1–100.0 μM),
Indomethacin (0.1–100.0 μM), Zileuton (0.1–100.0 μM), BWB70
(0.1–100.0 μM), BW A4C (0.1–100.0 μM), NCTT-956
(0.1–100.0 μM), PD146176 (0.1–100.0 μM), MK 561 (0.1–
100.0 μM), glutathione ethyl ester (1–10mM), L-oxothiazolidine-
4-carboxylate (1–10mM), cystamine (0.1–10.0 μM), and
nordihydroguaiaretic acid (0.1–10.0 μM). Cell viability was analyzed
24 hours after treatment. Cells were rinsed with warm phosphate-
buffered saline (PBS) and assessed by methyl thiazolyl tetrazolium
(MTT) assay. The fidelity of MTT assays in measuring viability was
verified by calcein-AM/ethidium homodimer-1 staining (Live/Dead
assay; Molecular Probes, Eugene, OR), following the manufacturer’s
instructions.
Collagenase-Induced Mouse Model of ICH
Male C57BL/6 mice (8–12 weeks of age; Charles River Labora-
tories, Wilmington, MA) were anesthetized with isoflurane
(2–5%) and placed on a stereotaxic frame. During the procedure,
the animal’s body temperature was maintained at 37C with a
homeothermic blanket. With a nanomite syringe pump (Harvard
Apparatus, Holliston, MA) and a Hamilton syringe, 1 μl of col-
lagenase (0.075IU; Sigma-Aldrich, St. Louis, MO) was infused
into the right striatum at a flow rate of 0.120 μl/min. Relative to
the bregma point, the stereotaxic coordinates of the injection
were as follows: lateral, −0.20; anteroposterior, 0.62; and dorso-
ventral, −0.40. In control animals, 1 μl of saline was infused.
The treatment group received NAC (75 and 300mg/kg dissolved
in vehicle [normal saline] and administered IP) once a day for
7 days starting at 2 hours after collagenase infusion. For combi-
natorial studies, NAC (40mg/kg, IP) and PGE2 (10 μM; intra-
cerebroventricular [ICV]) was administered 2 hours after
collagenase injection and then NAC (40mg/kg) alone was given
daily for 7 days. The control groups received vehicle (normal
saline) alone. Animals were randomized to sham or ICH groups.
Identity of mice that received vehicle or NAC was masked to
surgeons who performed the ICH. Identity was revealed after the
data were collected. Proper postoperative care was taken until
animals recovered completely. Similar surgical procedures were
used for rat experiments where 0.14U (0.7 μl) of collagenase was
infused into striatum (0.5mm anterior, 3.5mm lateral, and
6.5mm deep) under isoflurane anesthesia. Randomization and
blinding were also used.
Behavioral Analysis
The corner task assessed the integrated sensorimotor function in
both stimulation of vibrissae (sensory/neglect) and rearing (motor
response). Briefly, mice were placed between two cardboard
pieces forming a corner with a 30-degree angle. While maintain-
ing the 30-degree angle, the boards were gradually moved toward
the mouse until the mouse approached the corner, reared
upward, and turned 180 degrees to face the open end. The direc-
tion (left or right) in which the mouse turned around was
recorded for each trial. Ten trials were performed for each
mouse. For the sensory neglect task (adhesive tape removal task),
adhesive tape was placed on the planter region of the forward
paw (right and left) of mice. The time from which the tape was
applied to when the mouse successfully removed it was recorded
for each paw. A maximum of 300 seconds for each paw was
allowed.22 In the rat studies, a neurological deficit scale, the cor-
ner turn, tape removal, and staircase reaching tasks were used.
In Vivo Metal Distribution Imaging Analysis by x-
Ray Fluorescence Microscopy
Seven days following collagenase-induced ICH, mice were eutha-
nized and perfused with trace metal-free PBS. Brains were
removed and flash frozen with Freeze’it. Tissue was cut into
20-μm-thick sections and deposited on 4-μm-thick ultralene.
Iron and zinc content was imaged in the same samples using x-
ray fluorescence microscopy at beamline X27A at the National
Synchrotron Light Source. x-ray fluorescence spectra were col-
lected using an x-ray excitation energy of 11keV and a beam size
of 9 μm (vertical) × 17 μm (horizontal) in 15-μm steps, with an
integration time of 7 sec/pixel. Intensity for each metal was
quantified by integrating the area under the curve for the respec-
tive peak in the XRF spectrum (iron Kα = 6,405eV and zinc
Kα = 8,637eV). National Institute of Standards and Technology
thin film standard reference materials 1832 and 1833 were used
to calculate concentration and normalize for any differences
between the multiple beam time runs required to collect the
data. Molar concentrations were determined by dividing the
μm/cm2 values by the product of the volume of x-ray beam on
the sample (area × thickness of the sample), density of tissue
(estimated to be 0.9 g/cm3), and molecular weight of the
element.
Fluoro-Jade B Staining
Neurodegeneration was assessed in mice with collagenase-
induced ICH by analyzing staining with Fluoro-Jade B
(Millipore, Burlington, MA) carried out following the supplier’s
protocol. Briefly, 40-μM brain sections were mounted on
gelatin-coated slides and dried at room temperature overnight.
Sections were immersed in a graded series of alcohol solutions
before being immersed in a 0.06% potassium permanganate
(KMnO4) solution for 15 minutes. Sections were washed with
water before being immersed in a 0.001% Fluoro-Jade staining
solution for 30 minutes with gentle shaking in the dark. Sections
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were then washed with water and then dried overnight at room
temperature in the dark before being dehydrated and cover-
slipped with DPX (Sigma-Aldrich). Fluoro-Jade B staining was
examined within perihematoma regions using a fluorescence
microscope (Zeiss Axiovert; Carl Zeiss, Jena, Germany). Quanti-
tation of Fluoro-Jade B staining was performed from three brain
sections (anterior to posterior of hematoma) using Metamorph
analysis (Molecular Devices, LLC, San Jose, CA). In rats, total
lesion volume was determined at 14 or 28 days post-ICH.
Measurement of Eicosanoids
Analysis of oxidation products of arachidonic acid and other
polyunsaturated fatty acids, such as leukotrienes, prostaglandins,
and F2-IsoP, were carried out at the Eicosanoid Core Laboratory
at Vanderbilt University Medical Center (Nashville, TN).
Briefly, lipid species were measured in control and ICH brains
using gas chromatography/negative ion chemical ionization mass
spectrometry (GC/MS). The methods used have been published
in detail previously.41
Transcriptomic Analysis
Weighted Gene Coexpression Network Analysis (WGCNA) was
performed using the R package (R Foundation for Statistical
Computing, Vienna, Austria), as previously described.23,24
Briefly, correlation coefficients were constructed between expres-
sion levels of genes, and a connectivity measure (topological
overlap; TO) was calculated for each gene by summing the con-
nection strength with other genes. Genes were then clustered
based on their TO, and groups of coexpressed genes (modules)
were identified. Each module was assigned a color, and the first
principal component (eigengene) of a module was extracted from
the module and considered to be representative of the gene
expression profiles in a module. The phenotypic trait of interest
was then regressed on the eigengene to examine whether there
was a significant relationship between the module and trait. For
modules that showed a statistically significant relationship with a
phenotypic trait of interest (presence of ICH), gene ontology
and pathway analyses were conducted. Enrichment of genes for
specific ontologies and pathways was analyzed using Enrichr
(23586463), and corrected p values were used. An independent
list of coexpressed genes was obtained from COEXPRESdb (ver-
sion 6.0; 25392420).
Quantitative Real-Time PCR
Total RNA from cells and tissues were isolated using the
NucleoSpin RNA II kit (MACHEREY-NAGEL GmbH &
Co. KG, Düren, Germany), according to the manufacturer’s pro-
tocol. Duplex real-time PCR reactions were performed with gene
expression assays using 6-carboxyfluorescein–labeled probes
(Applied Biosystems, Foster City, CA) for ALOX5
(Mm 01182747_m1) and ALOX5 AP (Mm 01218551_m1).
Expression levels were normalized to β-actin gene expression
levels, which were determined with a VIC-labeled probe
(Applied Biosystems). All experiments were performed using a
7500 Real-Time PCR System (Applied Biosystems).
Adenoviral Overexpression of Antioxidant
Enzymes
Adenoviral constructs for managenese-containing superoxide dis-
mutase (MnSOD), catalase, and respective green fluorescent pro-
tein (GFP) control were obtained from ViraQuest, Inc. (North
liberty, IA), and adenoviral constructs for GSTA4, peroxiredoxin
3, and respective GFP control were purchased from Vector Bio-
Labs (Malvern, PA). Primary neuronal cultures were transduced
with all adenoviruses at a multiplicity of infection of 100 in
serum-free media for 1 hour at 370C and then were incubated in
complete plating media for 48 hours. Then, these neurons were
treated with hemin (100 μM) for 16 hours, and thereafter cell
survival was determined by MTT assay.
Immunoblot Analyses
Nuclear and cytoplasmic proteins were obtained using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Bio-
technology, Rockford, IL) in the presence of protease inhibitors
(phenylmethane sulfonylfluoride, MG132), according to the
manufacturer’s protocol. For determination of catalase and
MnSOD levels, cells were lysed in RIPA-B (1% Triton X-100,
1% sodium dodecyl sulfate, 50mM of Tris-Cl [pH 7.4],
500mM of NaCl and 1mM of ethylenediaminetetraacetic acid)
buffer before being diluted with Laemmli buffer and boiled. All
samples and were electrophoresed under reducing conditions on
NuPAGE Novex 4% to 12% Bis-Tris Gel polyacrylamide gels
(Invitrogen, Carlsbad, CA) before being transferred to a nitrocel-
lulose membrane (Bio-Rad Laboratories, Hercules, CA). For
detection of specific proteins, the following primary antibodies
and dilutions were used: ALOX-5 (610694; BD Biosciences, San
Jose, CA), MnSOD (HPA001814; Sigma-Aldrich), catalase
(C0979; Sigma-Aldrich), and β-actin (A2066 and A5316;
Sigma-Aldrich) were diluted in Odyssey blocking buffer, and
membranes were incubated overnight at 4C. After three washes
with Tris-buffered saline with Tween-20, membranes were incu-
bated in fluorophore-conjugated Odyssey IRDye-680 or IRDye-
800 secondary antibody (LI-COR Biosciences, Lincoln, NE) for
1 hour at room temperature. Finally, proteins were detected
using an Odyssey infrared imaging system (LI-COR
Biosciences).
Lipoxygenase UV-Vis-Based Half Maximal
Inhibitory Concentration IC50 Assay
Inhibition potencies were determined by following the formation
of the conjugated diene products, 5-HpETE [ε = 27,000M–1
cm–1 for arachidonic acid [AA] turnover) at 234nm with a Perki-
nElmer Lambda 40 UV/Vis spectrophotometer (PerkinElmer,
Waltham, MA), as described previously.25 All reaction mixtures
were 2ml in volume and constantly stirred using a magnetic stir
bar at room temperature (23C). All reactions were carried out
in Buffer A containing 200 μM of adenosine triphosphate and
10 μM of AA. AA concentration was verified by full turnover
with soybean-1 lipoxygenase and quantitating product concentra-
tion. Inhibitors were stored in dimethyl sulfoxide (DMSO) at –
20˚C. Enzymatic reactions were initiated by the addition of
approximately 100 to 300nM of ammonium sulfate–precipitated
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wild-type enzyme. Half maximal inhibitory concentration values
were obtained by determining the enzymatic rate at a minimum
of five inhibitor concentrations and plotting them against inhibi-
tor concentration, followed by a hyperbolic saturation curve fit.
Inhibitor concentrations were assayed in duplicate or triplicate,
depending on the quality of the data.
Statistical Analyses
Results are expressed as means ± standard error of the mean
(SEM) of multiple individual experiments, each carried out in
triplicate. Unless stated otherwise, the statistical analysis was car-
ried out with GraphPad Prism software (version 5; GraphPad
Software Inc., La Jolla, CA. One-way analysis of variance
(ANOVA) with Bonferroni’s or Dunnett’s multiple comparisons
post-hoc test was used if more than two groups were compared,
and a two-way ANOVA with Bonferroni’s post-hoc test if two
independent variables were compared.
Results
NAC Abrogated Hemin Toxicity In Vitro,
Reduced Neuronal Death, and Improved
Functional Recovery in an in vivo Model of ICH
To investigate the effects of NAC on hemorrhagic stroke,
we first examined its ability to protect neurons from
hemin-induced toxicity. Hemin is the oxidized form of
heme, which is released from hemoglobin following eryth-
rocyte lysis. It has been implicated in secondary injury fol-
lowing ICH. Treatment of primary cortical neurons with
100 μM of hemin induced cell death, as quantitated with
MTT and confirmed by qualitative live (green) and dead
(red) staining (Fig 1A) through a ferroptotic mechanism.10
Treatment with NAC abrogated hemin-induced ferropto-
sis (half maximal effective concentration [EC50] = 500
μM; Fig 1B), and NAC could be delivered 2 hours fol-
lowing hemin exposure and protect all cells. To determine
whether NAC (300mg/kg) is effective for treatment of
ICH in mice, we injected collagenase into the mediolateral
striatum to break down the basal lamina and induce stria-
tal brain bleeding. Collagenase injection simulates the
spontaneous rupture of an intraparenchymal vessel with
bleeding into the tissue over several hours.26 We assessed
neuronal loss from sections of mice treated with vehicle or
NAC (300mg/kg, IP administration) initially delivered
2 hours following experimental ICH and daily up to
7 days following the ictus using a nonspecific marker of
neurodegeneration, Fluoro-Jade (Fig 1C). As expected,
NAC (300mg/kg) reduced neuronal degeneration in peri-
hematomal regions of the mouse brain (Fig 1D,E). Mice
with striatal hemorrhage showed a preference for ipsilateral
turns because of deficits in the weight-balancing move-
ments of the limbs contralateral to the injury, as well as
spatial neglect. These deficits were corrected by 300mg/kg
of NAC, but not 75mg/kg of NAC, as measured by the
corner turn task (Fig 1F). Moreover, analysis of the tape
removal task (a test of sensory neglect) also improved sig-
nificantly in NAC-treated mice 1, 3, and 7 days after
ICH, but again only at the highest dose (300mg/kg; Fig
1G). Together, these findings demonstrate that NAC
(300mg/kg) reduces cell death in vitro and in vivo and
improves behavior after ICH in mice. Examination of
NAC in a collagenase ICH model in rats showed that
40mg/kg was the highest dose tolerated without toxicity.
Higher doses that were effective in mice (300mg/kg)
caused significant toxicity in rats, including paralytic ileus
and/or death (not shown). Of note, like mice, NAC deliv-
ered at 40 or 75mg/kg in rats 2 hours post-ICH was not
effective in reducing lesion volume or improving func-
tional recovery, suggesting that not only efficacy, but also
safety of NAC will be important in translating positive
findings from mice to humans.
NAC Did Not Influence Collagenase Enzyme
Activity or Bulk Iron Chelation
To address the mechanism of NAC protection in hemor-
rhagic stroke in mice, we first verified that NAC’s protec-
tive effects do not result from its influence on collagenase
enzyme activity, which was used to induce brain hemor-
rhage. Accordingly, we treated mice 2 hours post-ICH
with NAC and sacrificed them after 24 hours and assessed
hematoma volume (Fig 2A). Measurements of hematoma
size 24 hours after collagenase injection verified that NAC
(75 or 300mg/kg) does not inhibit collagenase activity in
mice (Fig 2B–D), demonstrating that the significant
behavioral benefits cannot be attributed to suppression of
collagenase activity by NAC.
NAC has been shown to be able to chelate metals,
including iron, and it is established that small molecules
with iron-binding capacity can improve outcomes in
ICH.22,27,28 Accordingly, we asked whether NAC affects
total iron levels in the CNS. We measured total iron in
the brain sections from saline and NAC-treated ICH mice
at 7 days by x-ray fluorescence microscopy. As expected,
ICH dramatically increased iron levels; however, NAC
had no effect on iron levels or distribution following ICH
(Fig 2E,F). These findings suggest NAC acts to protect
from ICH independent of its effects on total iron levels or
distribution in the CNS.
NAC Failed to Synergize With Other
“antioxidants” as Part of a Previously Validated
Cocktail
One strategy for identifying putative targets of NAC is to
assess its ability to synergize with antioxidants with estab-
lished, single target of action. A lack of synergy would sug-
gest target congruence between the antioxidant with a
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FIGURE 1: N-acetylcysteine (NAC) abrogated hemin-induced ferroptosis in primary neurons in vitro and reduced cell death and
enhanced functional recovery in a collagenase ICH model in mice. (A) Representative images of primary cortical neurons 24 hours
after treatment with saline, NAC (1mM), hemin (100 μM) and hemin (100 μM) + NAC (1mM). LIVE/DEAD assay; green
fluorescent cells labeled with calcein-AM are alive; red fluorescent cells labeled with ethidium homodimer are dead. Scale bars,
100 μm. (B) NAC protected primary cortical neurons from hemin-induced ferroptosis in a concentration-dependent manner. Cell
death was analyzed 24 hours after hemin treatment with or without NAC by monitoring MTT reduction, a population measure of
cell viability. (C) Experimental design for delivery of NAC post-ICH in mice. NAC (75mg and 300mg/kg; intraperitoneal) was
delivered 2 hours after collagenase injection and then daily for 7 days. Behavior was assessed using the corner task (spatial
neglect) and adhesive tape removal task (sensory neglect) and was assessed on days 1, 3, and 7 after ICH. (D) NAC reduced
neuronal degeneration was monitored by Fluoro-Jade (FJ) staining (green) in the perihematomal regions of the mouse brain.
Representative images show increased numbers of degenerating neurons (white arrows) in the ICH-treated group; this was
reduced by NAC treatment. Scale bar, 100 μm. (E) Quantification of FJ staining of neurons, a nonspecific marker of
degeneration, after NAC treatment in ICH mice brains. (F) NAC (300mg/kg) significantly reduces spatial neglect associated with
ICH. (G) NAC (300mg/kg) reduces sensory neglect (adhesive tape removal task) induced by ICH (n = 11). NAC (75mg/kg) had no
significant effect in mice or rats (not shown). Significance was determined by two-way ANOVA and Bonferroni’s post-hoc test.
All graphs are mean ± SEM. ANOVA = analysis of variance; ICH = intracerebral hemorrhage; NAC = N-acetylcysteine;
MTT = methyl thiazolyl tetrazolium; SEM = standard error of the mean.
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known target of action and NAC. Trolox is a water solu-
ble analog of vitamin E and a scavenger of lipid peroxyl
radicals, whereas α-lipoic acid (LA) is a known thiol active
compound that acts as a cofactor for many mitochondrial
enzymes, thus reducing mitochondrial superoxide produc-
tion. We selected these for initial investigation because a
previous study by Pujol et al established that a cocktail of
antioxidants (NAC, trolox, and α-lipoic acid) diminished
disease progression and reversed axonal damage in a
mouse model of X-linked adrenoleukodystrophy.29 To
investigate the effects of NAC, trolox, and LA individually
and in combination, we studied their effects in mouse cor-
tical neurons exposed to hemin. Treatment of NAC or
trolox, individually, dose dependently abrogated hemin-
induced toxicity (Fig 3A). However, LA failed to prevent
hemin toxicity at any dose examined (Fig 3A). To exam-
ine synergy, we tested subthreshold concentrations of the
antioxidants (eg, NAC and trolox) together in hemin
model. Interestingly, all combinations of the cocktail of
antioxidants failed to provide any synergistic protection
against hemin toxicity in primary cortical neurons, which
would be consistent with a convergent mechanism at the
level of lipid peroxidation, an established target of the vita-
min E analog, trolox (Fig 3B).
NAC Prevented Hemin-Induced Death by
Neutralizing Toxic Lipids Generated by Nuclear
ALOX5
Reactive lipid oxidants can be produced enzymatically by
specific enzymes or nonenzymatically by direct oxidant
FIGURE 2: N-acetylcysteine (NAC) enhanced functional recovery following intracerebral hemorrhage (ICH) without influencing
collagenase activity in vivo or iron levels or iron distribution in the brain after ICH. (A) Schematic illustration of NAC treatment,
post-ICH. (B) Serial brain sections from saline-, ICH-, and ICH + NAC–treated groups. (C,D) Quantification of hematoma size and
brain edema by light microscopy revealed no significant difference between control and NAC-treated groups in mice (n = 6).
(E) x-ray fluorescence microscopy analysis of pseudo-colored images from coronal sections of collagenase alone or NAC treatment
in collagenase-induced ICH in mice after 7 days. Quantification in cortex, hematomal, and perihematomal regions revealed that
total iron does not change in the brain following NAC treatment (F). Significance determined by one-way ANOVA followed by
Dunnett’s comparison test, for vehicle treatment ICH or NAC treatment (C,D). All graphs are mean ± SEM. ANOVA = analysis of
variance; ICH = intracerebral hemorrhage; NAC = N-acetylcysteine; ns = not significant; SEM = standard error of the mean.
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modification. Because NAC appeared to be targeting oxi-
dized lipids, we used structurally diverse, but well-charac-
terized, pharmacological tools to further understand how
hemin kills neurons. Neuronal membranes are composed
of phospholipid bilayers in which AA is esterified into
phosphatidylcholine, phosphatidylserine, and phosphatidy-
linositol. Following brain injury, AA is liberated by
increases in calcium-dependent, phospholipase A2 or
phospholipase C activity.30 Released AA can be oxidized
nonenzymatically by oxidants or enzymatically (by cyclo-
oxygenase [COX], lipoxygenase, or epoxygenase enzymes)
to produce bioactive lipid mediators (isoprostanes, hydro-
xynonenol, malondialdehye, hydroxyl-PUFAs [HETEs],
epoxy-PUFAs [EETs], prostaglandins, and leukotrienes)
FIGURE 3: Systematic pharmacological characterization of arachidonic acid metabolizing enzymes in hemin-induced ferroptosis in
primary cortical neurons identified 5-Lipoxygenase (ALOX5) as a target. (A) N-acetylcysteine (NAC), a cysteine prodrug, or Trolox
(TRO) dose dependently prevented hemin-induced ferroptosis in primary cortical neurons as measured by MTT assay. Lipoic acid
(LA) failed to prevent hemin-induced ferroptosis in primary cortical neurons. (B) Combinations of nonprotective concentrations of
NAC, TRO, or LA failed to synergize in preventing hemin-induced ferroptosis in primary cortical neurons. (C) Table illustrates that
structurally diverse inhibitors of 5-lipoxygenase, but not inhibitors of other arachidonate metabolizing enzymes, prevent hemin-
induced ferroptosis in primary cortical neurons. (D) Assay of recombinant ALOX5 activity in vitro (test tube) showed that putative
ALOX5 inhibitors are potently effective in inhibiting the enzyme, whereas NAC is not. Significance was determined by two-way
ANOVA and Bonferroni’s post-hoc test. ANOVA = analysis of variance; MTT = methyl thiazolyl tetrazolium.
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that regulate a diverse set of homeostatic and inflammatory
processes.31 We performed a systematic characterization of
AA metabolizing enzymes involved in hemin-induced toxic-
ity by using a cassette of known, but diverse, chemical
inhibitors. Selective inhibitors of epoxygenases (MS-
PPOH), COX-1 (aspirin), COX-2 (celecoxib; indometha-
cin), 12-LOX (NCTT-956), or 15-LOX (PD146176)
failed to protect against hemin toxicity (Fig 3C). However,
structurally diverse ALOX5 inhibitors (Zileuton, EC50 = 7
μM; BW B70, EC50 = 4 μM, and BW A4C, EC50 = 5
μM) significantly reduced hemin-induced toxicity in pri-
mary cortical neurons (Fig 3C). Test-tube assays involving
recombinant ALOX5 verified that each of these inhibitors
inhibits ALOX5 activity with high potency, whereas NAC
(Fig 3D) and β-carotene (not shown), which were also pro-
tective, did not (Fig 3D). These data suggest that
5-lipoxygenase–derived lipid metabolites are necessary for
hemin-induced ferroptosis in vitro. They also raise the pos-
sibility that NAC, trolox, and β-carotene are acting to neu-
tralize the toxic metabolic products of ALOX5 activity
rather than ALOX5 activity itself. These findings predicted
that inhibitors of arachidonate-5-lipoxygenase activating
protein (FLAP), an integral membrane protein within the
nuclear envelope, which serves to recruit ALOX5 to the
membrane, should also be protective. As expected, a chemi-
cal FLAP inhibitor (MK 561) also significantly reduced
hemin-induced death (Fig 3C).
ICH Induced Nuclear ALOX5 Protein and
ALOX5-Derived Gene Expression in Rodents and
Humans
Our pharmacological data support the hypothesis that
ALOX5 mediates death in vitro ICH by localizing to the
nuclear envelope by interactions with FLAP. Previous stud-
ies have shown that ALOX5 protein levels increase at the
nuclear envelope to release leukotrienes and attract inflam-
matory cells.32 Accordingly, we wanted to determine
whether ICH induces ALOX5 levels in the cytoplasm or
nucleus and to assay whether ALOX5-derived AA species
are increased following ICH (Fig 4A). To address this ques-
tion, we first analyzed protein levels of ALOX5 in the
nucleus after ICH. Immunoblot analysis of the cytosolic
and nuclear fraction after ICH revealed that ALOX5 signif-
icantly increases in the nucleus (Fig 4B). ALOX5 metabo-
lizes AA to produce 5-hydroperoxyeicosatetraenoic acid
(5-HPETE), which can then form inflammatory mediators
leukotriene B4 (LTB4) and cysteinyl leukotrienes (CysLTs;
including LTC4, LTD4, and LTE4).33 To assess whether
ALOX5 is activated in a rodent model of ICH, we moni-
tored its metabolites by GC/MS. GC/MS analysis of ICH
striatum showed a significant time-dependent increase in
the ALOX5 products, 5-HETE, LTB4, and LTE4 (Fig
4C–E). These findings are consistent with previous tran-
scriptomic analyses of brain tissues from human ICH
patients that identified an increased expression of mRNAs
encoding ALOX5 and 5-LO–activating protein FLAP
(ALOX5 AP).34
To further explore the network of transcripts coex-
pressed with ALOX5, we reanalyzed the human gene
expression data from Carmichael et al (including eight con-
trol samples and six samples from patients with ICH),
using WGCNA, a systems biology approach used to iden-
tify networks of coexpressed genes in relation to phenotypic
data.23,24 WGCNA identified 21 groups of coexpressed
genes, or modules, and ALOX5 was included in the green-
yellow module, a group of 302 transcripts overall upregu-
lated in ICH (Fig 4F). We queried a large transcriptional
database (http://coxpresdb.jp/cgi-bin/coex_list.cgi?gene=
240&sp=Hsa) and extracted the top 100 transcripts corre-
lated with ALOX5 (Fig 4G). Functional annotation of this
module revealed over-representation of genes involved in
inflammation in general and neutrophil degranulation spe-
cifically. Functional annotation of these transcripts revealed
similar ontology terms. Fifteen of these 100 transcripts were
included in the WGCNA greenyellow module, a significant
overlap (p = 8 × 10E-9, hypergeometric test) providing
independent validation of the WGCNA analysis (not
shown). These findings suggest ICH induces accumulation
of ALOX5 in the nucleus to increase ALOX5-derived lipid
species, which can trigger cell death (Fig 4) and/or represent
a signal sent from the nuclear envelope of dead cells to trig-
ger inflammation.32,35
Germline Deletion of ALOX5 or Pharmacological
Reduction of Its Expression by NAC Leads to
Neuroprotection and Improved Behavioral
Recovery
Our model suggests that NAC should neutralize
ALOX5-derived lipid species. Because hemin leads to
increases in ALOX5 protein in the nucleus, we examined
whether hemin also induced increases in ALOX5 and
ALOX AP mRNA levels and whether this was inhibited
by NAC. Consistent with our protein data (Fig 4B),
hemin time dependently induced ALOX AP and ALOX5
mRNA. Unexpectedly, NAC significantly suppressed these
increases in vitro as well as in vivo in mice (Fig 5A–D). If
ALOX5 and its products are targets for NAC treatment,
then ALOX5 deletion should be sufficient for neuropro-
tection and functional recovery following ICH.
We therefore induced ICH in wild-type and ALOX5
knockout mice. As expected, molecular knockdown of
ALOX5 significantly improved somatosensory function at
3 and 7 days following ICH (Fig 5E,F). Collectively, these
findings are consistent with a model of injury in ICH
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where hemin, by as yet unclear mechanisms, induces
ALOX5 activity at the nuclear envelope. In a feed-forward
manner, these metabolites increase ALOX5 and FLAP tran-
scription and activity, generating adequate reactive lipid
species to mediate ferroptotic cell death with features of
necrosis. Necrotic cells could then release leukotrienes from
the nuclear envelope to activate the inflammatory
response.32 Our human data suggested that transcriptional
induction of ALOX5 occurs temporally in concert with
neutrophil degranulation, possibly coupling cell-death
mechanisms with the inflammatory response (Fig 4G).
Converging data suggest that ICH-induced ALOX5 triggers
cell death and impairment following ICH in mice.
NAC Reduced the Lipid Protein Adducts and
Efficacy Required Increased Levels or Flux in
Glutathione and Its Protection Is Mimicked by
GSTA4
Given the unexpected effects of NAC on ALOX5 tran-
scription, it is formally possible that NAC acts up- and/or
FIGURE 4: Intracerebral hemorrhage (ICH)-induced ALOX5-derived oxidized lipids and gene expression in mice and humans.
(A) Schematic model of ALOX5 pathway activation in ICH. (B) ICH increased ALOX5 protein levels in the nuclear fraction as verified by
immunoblot analysis. Gas chromatography/mass spectrometry analysis revealed a significant increase in ALOX5-derived lipid species
after ICH in rats (n = 4) compared to sham, including 5-hydroxyeicosatetraenoic acid (5-HETE) (C), Leukotriene B4 (LTB4) (D), and
Leukotriene E4 (E). Data from sham control brains from each time point were pooled for the analysis. (F) Transcriptomic analysis of
brain tissues from control (n = 8) and ICH (n = 6) patients. (G) Weighted gene coexpression network analysis (WGCNA) revealed
transcripts most closely coregulated with ALOX5. Significance was determined by one-way ANOVA and Dunnet’s multiple-comparison
test. All graphs are mean ± SEM. ANOVA = analysis of variance; ICH = intracerebral hemorrhage; SEM = standard error of the mean.
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downstream of ALOX5 transcriptional induction. What-
ever the site(s) of action, the model further predicts that
NAC, trolox, and more-selective ALOX5 inhibitors
should inhibit incorporation of ALOX5-derived reactive
lipids into proteins. Electrophilic attack by ALOX5 prod-
ucts could alter cellular protein-mediated signaling to trig-
ger cell death. To detect covalent lipid protein adducts,
we used AA tagged with biotin (Bt-AA) followed by west-
ern blots of lysates probed with streptavidin/horseradish
peroxidase, as previously described.37 As expected, Bt-AA
incorporation into protein increased with increasing con-
centrations of hemin (Fig 6A). Nonprotective doses of
NAC (0.1mM), vitamin E (1 μM), or zileuton (ALOX5
inhibitor, 1 μM) did not decrease AA-protein adduct for-
mation. However, protective doses of NAC (1mM), vita-
min E (10 μM), or zileuton (10 μM) decreased lipid
protein adduction formation (Fig 6B; see arrow). Quanti-
fication of the intensity of the experimental bands revealed
that NAC, Vit E, and zileuton (an ALOX5 inhibitor) all
inhibit lipid protein adduct formation (Fig 6C). The
bands that are evident in the control wells are the endoge-
nous biotin containing carboxylases and are an additional
confirmation of equal gel loading between groups.38 These
results suggest that reactive lipids incorporated into
FIGURE 5: N-acetylcysteine (NAC) reduced ICH-induced ALOX5 gene expression and molecular knockdown of ALOX5 improves
ICH-induced behavioral deficits. RT-PCR analysis revealed that toxic levels of hemin time dependently (4, 8, and 12 hours)
increased ALOX5 and ALOX activating protein (AP) levels in primary neurons. Protective doses of NAC (1mM) blocked this
expression in primary cortical neurons (A,B). In mice, NAC significantly blocked ICH-induced ALOX5 (C) and ALOX AP levels (D).
Molecular knockdown of ALOX5 improved spatial neglect behavioral deficits and sensory neglect (adhesive tape removal task)
behavioral deficits associated with ICH compared to WT controls. Significance was determined by two-way ANOVA and
Bonferroni’s post-hoc test. All graphs are mean ± SEM. ANOVA = analysis of variance; ICH = intracerebral hemorrhage;
NAC = N-acetylcysteine; SEM = standard error of the mean; WT, wild type.
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proteins are abrogated by ALOX5 inhibitors, NAC, or
vitamin E and are consistent with the ability of ALOX5
metabolites to incorporate into proteins to induce
changes in signaling or dysfunction and induce cell
death. The catalytic action of ALOX5 involves the for-
mation of site-specific alkyl and lipid peroxyl radicals,
which are generally not released from the enzyme and
not then accessible to lipid radical scavenging agents,
such as vitamin E, which cannot access the catalytic site
of the enzyme. However, low levels of the lipid radicals
can exit the active site and, if this occurs, are capable of
initiating lipid peroxidation and in this case can be
quenched by selective ALOX5 inhibitors or chain-
breaking antioxidants such as vitamin E or NAC (Fig
6C). Cell death can be neutralized by specific ALOX5
inhibition or by NAC, which neutralizes lipid species
downstream of ALOX5 activity and prevents the feed-
forward increases in ALOX5 and FLAP expression and
ferroptotic cell death (Fig 1) and, although not directly
explored here, possibly inflammation.32
In this scheme, NAC could interact directly with
reactive lipids, or, alternatively, it could act by increasing
FIGURE 6. Legend on next page.
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concentrations and/or flux of cysteine, the rate-limiting
precursor for glutathione, a versatile, tripeptide antioxi-
dant.12,21 To determine whether NAC-induced protection
from hemin requires glutathione, we inhibited glutathione
synthesis using buthionine sulfoximine (BSO), a selective
inhibitor of the enzyme, γ-glutamylcysteine synthetase,
the rate-limiting step in glutathione synthesis,21 and deter-
mined whether NAC-induced protection could be abro-
gated. As expected, NAC dose dependently increased total
glutathione levels in the presence or absence of hemin,
although in the presence of hemin absolute levels were
reduced (Fig 6D). Consistent with the notion that gluta-
thione is required for NAC protection from hemin-
induced ferroptosis, we found that BSO significantly
reduced NAC’s beneficial effects (Fig 6E). The results pre-
dicted that other strategies that also lead to increased glu-
tathione levels in neuronal cultures should also abrogate
hemin-induced ferroptosis. As expected, increasing gluta-
thione with a membrane permeable form of glutathione,
glutathione ethyl ester, by adding the cysteine prodrug, L-
oxothiazolidine-4-carboxylate (OTC39), or by addition of
the established transcriptional activators of nuclear factor
erythroid 2–related factor 2 (Nrf2) and glutathione syn-
thesis, cystamine, or nordihydroguaiaretic acid (NDGA40)
prevented hemin-induced ferroptosis as effectively as NAC
in vitro (Fig 6F). Together, these results suggest that
NAC acts to increase glutathione to prevent ALOX5
induced ferroptosis.
Glutathione can act by several glutathione-
dependent enzymes to neutralize reactive lipids, including
GSTs. One GST isoform, GSTA4, has been specifically
implicated in this role.41,42 Accordingly, adenoviral over-
expression of GSTA4 in primary cortical neuronal cultures
protected against hemin-induced toxicity (Fig 6G). As
controls for specificity of this effect, we overexpressed
other “glutathione-independent” antioxidants, such as
MnSOD, catalase, and peroxiredoxin, which target super-
oxide (MnSOD) or hydrogen peroxide (catalase, peroxre-
doxin) in the cytosol or mitochondria, As expected, we
did not find that forced expression of any of these
enzymes could protect against hemin-induced toxicity.
Although our results do not establish whether chemical or
molecular agents are acting in glia or neurons or both,
these findings are consistent with a model in which NAC
increases reduced glutathione and the activity of
glutathione-dependent antioxidant enzymes (eg, GSTA4)
to nullify toxic reactive lipid species.
Targeted Lipidomics Identified Expected
Increases in ALOX5 Metabolites in ICH and a
Prosurvival Prostaglandin, PGE2, Which
Synergized With NAC in ICH
As described above, we observed expected increases of
ALOX5 metabolites in vivo in rats following ICH (Fig 4).
Our mass spectrometric analysis from rats also revealed
that ICH-induced COX-dependent lipid species (Fig 7A),
including PGE2, prostaglandin D2 (PGD2), prostaglandin
F2 (PGF2), and 6-keto-prostaglandin F2 (6keto-PGF2), are
increased following ICH (Fig 7C–F). Interestingly, F2-iso-
prostanes, which are a marker of nonenzymatic lipid per-
oxidation, were not increased (Fig 7B). Collectively, these
data suggest that AA metabolites downstream of ALOX5
and COX are increased following ICH, whereas a canoni-
cal nonenzymatic lipid species, F2 isoprostanes, are not.
The findings are consistent with previous observations
from several labs that showed that COX-2 and down-
stream metabolic enzymes are induced following
ICH.43,44
Although a number of prostaglandin species down-
stream of COX-2 activity were induced following ICH,
FIGURE 6: Protective NAC reduced lipid protein adducts and required glutathione (GSH) synthesis for neuroprotection.
(A) Primary cortical neurons were treated with progressively higher concentrations of hemin. Lipid protein adducts (arachidonic
acid-biotin) were detected by western blots probed with streptavidin-HRP (horseradish peroxidase). (B) NAC (1mM),
α-tocopherol (10 μM), and Zileuton (10 μM) attenuated hemin-induced oxidized lipid protein adducts. Grayscale image of lipid
protein adducts probed with streptavidin-HRP. Representative blot from replicates of three experiments. (C) Quantification of
bands reveals a significant reduction in oxidized lipid protein adducts after NAC, Zileuton, and vitamin E. (D) High-performance
liquid chromatography analysis of total GSH revealed that NAC increases GSH levels in control and hemin-treated cortical
neurons. (E) Pharmacological inhibition of γ-glutamylcysteine synthetase, the rate-limiting enzyme in GSH synthesis, by BSO
blocked the ability of NAC to prevent hemin-induced ferroptosis in primary cortical neurons. (F) As predicted from results in (B),
table shows that multiple established strategies to increase GSH levels in neurons or glia prevented hemin-induced ferroptosis.
GSH ethyl ester (a membrane permeant form of GSH); L-oxothiazolidine-4-carboxylate (OTC), a cysteine donor; Nrf2 activators
cystamine and NDGA, which increase GSH synthesizing and GSH-dependent detoxification enzymes, abrogate hemin-induced
ferroptosis in primary cortical neurons as measured by MTT assay. (G) Adenoviral overexpression of GSTA4, a GSH enzyme
known to neutralize toxic lipids, protects against hemin-induced ferroptosis. (H) Representative immunoblot for forced
expression of antioxidants. (I) Overexpression of MnSOD, catalase, and peroxiredoxin 3 failed to protect against hemin-induced
toxicity. Significance was determined by two-way ANOVA followed by Bonferroni’s comparison test. All graphs are mean ± SEM.
Ad GFP = adenoviral green fluorescent protein; ANOVA = analysis of variance; BSO = buthionine sulfoximine; EC50 = half
maximal effective concentration; MTT = methyl thiazolyl tetrazolium; NAC = N-acetylcysteine; ns = not significant;
SEM = standard error of the mean.
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we focused our attention on PGE2. Indeed, a zebrafish
model was used to show that PGE2 combined with NAC
synergistically prevented cell death from acetaminophen-
induced toxicity in liver. Acetominophen, like hemin, trig-
gers death by insufficient glutathione levels or flux (Fig 6;
see a previous work45. Accordingly, we asked whether
PGE2 would synergize with NAC protection against
hemin-induced ferroptosis in vitro. Despite modest pro-
tection from hemin-induced ferroptosis by 16,16 dimethyl
PGE2 (dmPGE2, a long-acting analog of PGE2) in cortical
neurons, treatment of NAC (100 μM) and dmPGE2
(10 μM) provided synergistic protection (Fig 8A). These
results showed that combinatorial treatment of dmPGE2
and NAC could reduce the concentration of NAC
required for protection by 10-fold in vitro. To determine
whether NAC and dmPGE2 would synergize to induce
functional recovery after ICH in vivo, NAC (40mg/kg;
IP, a dose ineffective in mice and rats) and dmPGE2
10 μM (ICV) was delivered 2 hours postinjury in mice,
and then NAC 40mg/kg was administered IP once-daily
for 7 days (Fig 8B). Whereas the combination of NAC
and dmPGE2 significantly reduced neuronal degeneration,
as monitored by Fluoro-Jade staining (green) in the peri-
hematomal regions of the mouse brain after ICH (Fig 8C,
D), NAC or dmPGE2 alone had no significant effect.
Behavioral studies following ICH showed that NAC plus
dmPGE2 combination significantly improves behavioral
deficits induced by ICH (Fig 8E,F), whereas either agent
alone had no effect. Of note, we attempted to evaluate the
combination of PGE2 plus NAC in rats, but again we
FIGURE 7: Intracerebral hemorrhage (ICH) in rodents induced COX-derived oxidized lipids. (A) Experimental design for analyzing
eicosanoid levels post-ICH in mice. (B) GC/MS analysis revealed that levels of F2 isoprostanes, established markers of nonenzymatic
lipid peroxidation, were not altered after ICH (n = 4). COX-derived species PGE2 (C), PGD2 (D), PGF2 (E), and 6-keto PGF2 (F) were
time dependently increased post-ICH (n = 4). Data from sham control brains from each time points were pooled for the analysis.
Significance was determined by one-way ANOVA and Dunnet’s multiple-comparison test. All graphs are mean ± SEM.
ANOVA = analysis of variance; COX = cyclooxygenase; GC/MS = gas chromatography/mass spectrometry; ICH = intracerebral
hemorrhage; PGD2 = prostaglandin D2; PGE2 = prostaglandin E2; PGF2 = prostaglandin F2; SEM = standard error of the mean.
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found critical species differences, in that rats, not mice,
revealed large changes in body temperature to 40C
(and probably high blood pressure), leading to a signifi-
cantly enlarged hematoma size, which likely explains the
significantly worsened lesion size with this PGE2/NAC
combination in rats. Together, these findings demonstrate
that combinatorial administration of NAC and PGE2 syn-
ergistically protects the brain, and reduces the concentra-
tions of NAC required to improve functional recovery
following ICH in mice, whereas side effects limit its utility
in rats.
Discussion
ICH, a stroke subtype, remains a significant cause of mor-
tality and morbidity around the world.2 Accordingly, there
is a need to identify therapeutic agents with known safety
in humans such as NAC to expand options for treating
FIGURE 8: Prostaglandin (PGE2) synergized with NAC to prevent hemin-induced ferroptosis in vitro and in improving functional
recovery following ICH in mice in vivo. (A) NAC in combination with PGE2 synergized against hemin-induced ferroptosis in primary
cortical neurons. (B) Schematic illustration of the combinatorial delivery of NAC (40mg/kg, intraperitoneal) and PGE2 (10 μM,
intracerebroventricular) after ICH in mice. The corner task (spatial neglect) and adhesive tape removal task (sensory neglect) were
assessed on days 1, 3, and 7 after ICH to assess behavioral improvement. (C) The NAC (40 mg/kg, intraperitoneal) and
intracerebroventricular (10 μM) PGE2 combination reduced neuronal degeneration as monitored by Fluoro-Jade staining (green)
in the perihematomal regions of the mouse brain after ICH. (D,E) Intraperitoneal NAC (40mg/kg) plus intracerebroventricular
PGE2 reduces spatial neglect and sensory neglect induced by ICH, whereas each agent alone does not (n = 10). Significance was
determined by two-way ANOVA and Bonferroni’s post hoc test. All graphs are mean ± SEM. ANOVA = analysis of variance;
ICH = intracerebral hemorrhage; NAC = N-acetylcysteine; ns = not significant; PGE2 = prostaglandin E2; SEM = standard error of
the mean.
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ICH. Whereas previous studies have suggested that NAC
has many potential targets in the CNS for preventing cell
death or enhancing functional recovery, our data point to
nuclear ALOX5-derived reactive lipid species as the target
of action for NAC in mediating neuroprotective effects in
an in vitro and an in vivo mouse model of ICH. First,
NAC failed to synergize with established lipid peroxida-
tion inhibitors, including trolox (a water-soluble form of
vitamin E; Fig 3B), vitamin E (not shown), or β-carotene
(not shown), consistent with them working on a conver-
gent pathway centered in lipid peroxidation and its prod-
ucts. Second, NAC protection in an in vitro model of
ICH (ferroptosis) was mimicked by structurally diverse
inhibitors of ALOX5, an AA-metabolizing enzyme that
produces signaling, reactive lipids (Fig 3C). Similarly,
molecular deletion of ALOX5 in mice improved func-
tional recovery after ICH (Fig 5E,F). Third, AA reacted
with protein following in vitro ICH, and the interaction
of proteins and reactive lipids was blocked by chemical
ALOX5 inhibition, a nonselective lipid peroxidation
inhibitor (vitamin E), or NAC (Fig 6B,C). Fourth, NAC
protection in vitro was dependent on glutathione levels or
flux, indicating that direct scavenging or reaction with
electrophiles is not required for NAC’s beneficial effects
(Fig 6). In further support of this finding, we found that
the effects of NAC were mimicked by other agents known
to increase cysteine (rate-limiting precursor of glutathi-
one), such as OTC, or increase glutathione (glutathione
ethyl ester; Fig 6F). Moreover, Nrf2 activators (cystamine,
NDGA),40 which induce glutathione synthesizing and
glutathione detoxification enzymes, transcriptionally also
prevent hemin toxicity (Fig 6F). Fifth, forced expression
of GST isoform (GSTA4), known to neutralize reactive
lipids in a glutathione-dependent manner, also prevented
hemin-induced toxicity in vitro (Fig 6G). Sixth, increases
in ALOX5 metabolites were observed following ICH in
mice and rats, suggesting that toxic factors downstream of
hemorrhage in vivo also produce reactive lipids (Fig 4).
Seventh, increases in ALOX5 and ALOX5 AP message are
observed in mice, rats, and humans; NAC treatment
decreased hemin-induced ALOX5 gene expression and
hemin-induced oxidized lipid species (Fig 5). Methods for
detecting incorporation of reactive lipids downstream of
ALOX5 in vivo are not currently available, suggesting that
other biomarkers will need to be developed as a proxy for
NAC’s ability to decrease ALOX5-derived reactive lipids.
Nevertheless, previous studies have shown that zileuton
can improve functional recovery following ICH in mice.36
Stoichiometric antioxidants, such as vitamin E or
cerovive (NXY-059), have been disappointing in the clinic
for stroke treatment, likely because the concentrations
required for these agents to be effective are relatively high
compared to therapeutic agents that work catalytically.
NAC also appears to act stoichiometrically to increase glu-
tathione and is used at relatively high concentrations
in vitro and in vivo (Fig 1). For stoichiometric antioxi-
dants, one molecule of antioxidant is required to neutral-
ize one oxidant. Accordingly, if the concentration of
antioxidant drug that reaches the CNS is below the level
of injury-induced oxidant production, then the agent will
be ineffective. Given that previous studies have not
attempted to establish a relevant target for antioxidants in
the required cell type(s), it has been difficult to establish
the optimal dose of stoichiometric antioxidants to use in a
clinical trial. Our studies suggest that following ICH,
5-lipoxygenase–derived lipids are important for cell death,
and thus provide a starting point for future studies aimed
at establishing target engagement for NAC in ICH in
humans. Indeed, previous transcriptomic analyses of brain
tissues from human ICH patients identified an increased
expression of mRNAs encoding ALOX5 and 5-LOX–
activating protein FLAP (ALOX5 AP).34 Additionally, a
recent study identified a polymorphism in the promoter
for FLAP (ALOX5 AP) that is associated with ICH in a
Korean population.46 The ability of NAC to abrogate
increases in ALOX5 and ALOX5 AP in hemin-induced
ferroptosis suggests a feed-forward model in which
ALOX5 products further augment levels of ALOX5 and
ALOX5AP. This provides a strong argument for getting
NAC to patients as early as possible at the appropriate
dose after ICH to confer maximal effect against cell death
as well as inflammation.
Targeted lipidomics of eicosanoids (signaling mole-
cules resulting from oxidation of 20 carbon arachidonic
acids) revealed that both products of ALOX5 and COX-2
are increased following ICH in vivo. We decided to focus
on the effects of PGE2, one product of COX-2 metabo-
lism, because of a previous study in zebrafish that showed
that PGE2 and NAC could synergize to improve the ther-
apeutic window and efficacy in preventing acetaminophen
toxicity.45 Similar to hemin-induced toxicity of neurons
in vitro, NAC-induced protection from acetaminophen
toxicity requires increases in levels of flux of glutathione,
so we considered the possibility that results from those
studies might inform our investigations as well. Remark-
ably, we found synergy between PGE2 and NAC in pre-
venting hemin-induced ferroptosis in vitro, and improving
recovery following collagenase-induced ICH in vivo in
mice. Of note, in vitro, we did not find that COX inhibi-
tors (which would be expected to diminish PGE2) wors-
ened hemin-induced death in mixed neuronal-glia cultures
(not shown). These findings raise the possibility that a cell
type other than neurons or glia is relevant for producing
PGE2 in ICH, and it is formally possible that PGE2 is
December 2018 869
Karuppagounder et al: NAC Synergizes With PGE2 to Improve Outcomes After ICH
produced by microglia or macrophages, which are not pre-
sent in our in vitro cultures. Whatever the source of PGE2
in ICH, our results are the first to demonstrate synergy
between NAC and PGE2 in protecting the brain. With
the advent of multiple strategies to deliver drugs to the
hematoma site, including minimally invasive surgery47 or
BrainPath,48 a combinatorial neuroprotective treatment
delivered right to the hematoma site is now feasible.
We do not understand the basis for synergy between
NAC and PGE2. Unexpectedly, we did not find that
ALOX5 inhibitors synergized with PGE2 (not shown),
raising the possibility that NAC may alter PGE2 signaling
directly rather than by its effects on ALOX5-derived prod-
ucts. Previous studies suggest that PGE2 affords neuropro-
tection against Aβ-induced toxicity in primary neurons
through EP2 or EP4 receptors, by cAMP/protein kinase
A–dependent pathway.44,49 Indeed, activation of EP2
receptor by PGE2 or agonist butaprost blocked hemin-
induced neuronal death.50 These findings contrast with
other studies that have shown that PGE2 activation of
EP3 receptors can worsen outcomes following ICH in
mice, raising the possibility that NAC enhances PGE2-
EP2/EP4 binding while diminishing PGE2-EP3 interac-
tions. Of note, in mice or rats low doses of NAC (40mg/
kg) were ineffective (Figs 1 and 8). We evaluated the
PGE2/NAC combination in rats, but unlike mice, rats
showed much greater increases in temperature (and proba-
bly blood pressure) in response to ICV infusion of 190ng
of PGE2. These effects lead to an increase in ICH hema-
toma size in rats, which we did not observe in mice. Until
this lack of species translation is understood, NAC and/or
PGE2 should not be considered for treatment of ICH in
humans. Indeed, future studies will focus on the mecha-
nism by which NAC and PGE2 synergize in vitro and
in vivo in mice as a strategy for moving this effective com-
bination safely into rats and humans.
We could not examine doses of NAC in rats
(300mg/kg) that were effective in mice because of dose-
limiting toxicity. Doses in rats that were well tolerated
(40mg/kg) were ineffective. Similar doses (40–75mg/kg)
in mice were also ineffective (Fig. 8C,D). Although it is
formally possible that the unexpected toxicity of NAC in
rats relates to the intraperitoneal delivery strategy we
used (NAC is delivered intravenously or orally in
humans), our results suggest that NAC may not have as
wide a therapeutic window as previously considered. Our
results in mice highlight that replication experiments in a
different species can fail not only because of lack of effi-
cacy, but also because of species differences in toxicity
(Fig 2).
A survey of trials involving NAC in neurological dis-
orders on clinical trials.gov reveals trials in process or
completed in a host of neurological conditions, including
subarachnoid hemorrhage, Parkinson’s disease, Alzhei-
mer’s disease, traumatic brain injury, autism, and schizo-
phrenia. Almost all studies chose doses of NAC that are
safe, but without clear elucidation of the dose required to
induce a therapeutic effect. Some studies are using MR
spectroscopy to monitor increases in glutathione or gluta-
mate with NAC, but, again, these studies and ours do not
establish a clear target for how much of an increase in glu-
tathione or glutamate is required for behavioral improve-
ment. Cerebrospinal fluid measurements could improve
fidelity of glutathione measurements, but a threshold level
of increase of glutathione has yet to be elucidated in any
paradigm.51 As we plan to try to avoid these enormous
challenges in moving our studies of NAC forward for
ICH, we will need to develop a good biomarker for
NAC’s therapeutic effect in humans. Given the ability of
PGE2 to synergize with NAC in mice to induce functional
recovery, it is our hypothesis that understanding precisely
how this combination is effective will provide the best
chances of neuroprotection with the widest therapeutic
window in humans, once a good biomarker for NAC effi-
cacy (possibly an ALOX5 metabolite) is identified.
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